CY1124569T1 - Φαρμακοτεχνικη μορφη που περιεχει γλυκοπυρρολικο, μεθοδος και συσκευη - Google Patents
Φαρμακοτεχνικη μορφη που περιεχει γλυκοπυρρολικο, μεθοδος και συσκευηInfo
- Publication number
- CY1124569T1 CY1124569T1 CY20201100560T CY201100560T CY1124569T1 CY 1124569 T1 CY1124569 T1 CY 1124569T1 CY 20201100560 T CY20201100560 T CY 20201100560T CY 201100560 T CY201100560 T CY 201100560T CY 1124569 T1 CY1124569 T1 CY 1124569T1
- Authority
- CY
- Cyprus
- Prior art keywords
- glycopyrrole
- air
- glycopyrrolate
- form containing
- pharmaceutical form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Γνωστοποιείται μια μέθοδος για την παρασκευή μιας φαρμακευτικής σύνθεσης για πνευμονική χορήγηση η οποία περιέχει ταυτόχρονη άλεση με πεπιεσμένο αέρα γλυκοπυρρολικού και στεατικού μαγνησίου, όπου τα ταυτόχρονα αλεσμένα με πεπιεσμένο αέρα γλυκοπυρρολικό και στεατικό μαγνήσιο υποβάλλονται έπειτα σε ένα στάδιο επεξεργασίας, το οποίο συμπεριλαμβάνει την έκθεση των ταυτόχρονα αλεσμένων με πεπιεσμένο αέρα γλυκοπυρρολικού και στεατικού μαγνησίου σε υγρασία. Γνωστοποιείται επίσης μια σύνθεση που παρασκευάζεται με αυτή τη μέθοδο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14184164 | 2014-09-09 | ||
PCT/EP2015/070660 WO2016038116A1 (en) | 2014-09-09 | 2015-09-09 | Formulation comprising glycopyrrolate, method and apparatus |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124569T1 true CY1124569T1 (el) | 2022-03-24 |
Family
ID=51542160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100560T CY1124569T1 (el) | 2014-09-09 | 2020-06-17 | Φαρμακοτεχνικη μορφη που περιεχει γλυκοπυρρολικο, μεθοδος και συσκευη |
Country Status (38)
Country | Link |
---|---|
US (2) | US10532041B2 (el) |
EP (2) | EP3191081B1 (el) |
JP (1) | JP6502501B2 (el) |
KR (1) | KR101927960B1 (el) |
CN (1) | CN106604720B (el) |
AP (1) | AP2017009777A0 (el) |
AR (1) | AR101793A1 (el) |
AU (1) | AU2015314272B2 (el) |
BR (1) | BR112017003888B1 (el) |
CA (1) | CA2960694C (el) |
CL (1) | CL2017000560A1 (el) |
CO (1) | CO2017003056A2 (el) |
CY (1) | CY1124569T1 (el) |
DK (1) | DK3191081T3 (el) |
DO (1) | DOP2017000065A (el) |
EA (1) | EA037332B1 (el) |
EC (1) | ECSP17021465A (el) |
ES (1) | ES2793905T3 (el) |
HR (1) | HRP20201005T1 (el) |
HU (1) | HUE049339T2 (el) |
IL (1) | IL250427A0 (el) |
LT (1) | LT3191081T (el) |
MA (2) | MA40617B1 (el) |
MX (1) | MX2017003080A (el) |
MY (1) | MY181647A (el) |
NZ (1) | NZ728435A (el) |
PH (1) | PH12017500303A1 (el) |
PL (1) | PL3191081T3 (el) |
PT (1) | PT3191081T (el) |
RS (1) | RS60299B1 (el) |
SG (1) | SG11201700536XA (el) |
SI (1) | SI3191081T1 (el) |
SV (1) | SV2017005403A (el) |
TN (1) | TN2017000077A1 (el) |
TW (1) | TWI602566B (el) |
UA (1) | UA115958C2 (el) |
WO (1) | WO2016038116A1 (el) |
ZA (1) | ZA201700658B (el) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3595631A1 (en) * | 2017-03-15 | 2020-01-22 | Vectura Limited | Method and formulation |
CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9808470D0 (en) | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
GB9826286D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
JP2004515260A (ja) | 2000-04-11 | 2004-05-27 | デュラ・ファーマシューティカルズ・インコーポレイテッド | 物理的に安定化された乾燥粉末製剤 |
ATE374261T1 (de) | 2000-07-20 | 2007-10-15 | Campina Nederland Holding Bv | Methode zur herstellung eines kristallinen tablettierungshilfstoffes, der so erhaltene hilfsstoff und seine verwendung |
CA2429665C (en) | 2000-11-30 | 2013-10-22 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
GB0030074D0 (en) | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
DE10212264A1 (de) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
ITMI20022674A1 (it) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
US7188993B1 (en) * | 2003-01-27 | 2007-03-13 | Harold W Howe | Apparatus and method for resonant-vibratory mixing |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
JO3102B1 (ar) | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0410398D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20060292077A1 (en) | 2005-03-18 | 2006-12-28 | Zhao Jonathon Z | Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same |
GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
EP1922150A1 (en) | 2005-07-07 | 2008-05-21 | Nanotherapeutics, Inc. | Process for milling and preparing powders and compositions produced thereby |
GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
JP5283835B2 (ja) * | 2006-07-06 | 2013-09-04 | 東京エレクトロン株式会社 | マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ |
EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
EP1944018A1 (en) | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
BRPI0819259A2 (pt) | 2007-11-07 | 2019-10-01 | Astrazeneca Ab | formulações de pó seco compreendendo derivados do ácido ascórbico. |
KR20100099281A (ko) | 2007-12-13 | 2010-09-10 | 노파르티스 아게 | 유기 화합물 |
EP2229148B1 (en) | 2007-12-13 | 2014-03-05 | Novartis AG | Process for preparing a particulate and crystalline drug substance |
US8235314B2 (en) | 2009-02-12 | 2012-08-07 | Linde Aktiengesellschaft | Nonequilibrium humidity control for jet milling |
US20120022127A1 (en) | 2009-04-09 | 2012-01-26 | Thomas Allmendinger | Process for preparing pyrrolidinium salts |
US20120160944A1 (en) | 2009-04-24 | 2012-06-28 | Aaron Dodd | Method for the production of commercial nanoparticle and micro particle powders |
BR112012024059B1 (pt) * | 2010-04-01 | 2021-06-01 | Chiesi Farmaceutici S.P.A. | Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco |
KR101863523B1 (ko) | 2010-04-21 | 2018-05-31 | 키에시 파르마슈티시 엣스. 피. 에이. | 정전하가 감소된 입자를 제공하는 방법 |
ES2546422T5 (es) | 2010-08-31 | 2023-01-20 | Glaxosmithkline Ip Dev Ltd | Productos medicinales de inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos |
CA2827045A1 (en) | 2011-02-17 | 2012-08-23 | Cipla Limited | Compositions of glycopyrrolate and a beta2-agonist |
JO3510B1 (ar) * | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
RU2013155903A (ru) | 2011-05-17 | 2015-06-27 | Перл Терапьютикс, Инк. | Композиции, способы и устройства для респираторной доставки двух или более активных средств |
GB201205632D0 (en) | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
EA201590030A1 (ru) | 2012-07-05 | 2015-09-30 | Арвен Айлак Санайи Ве Тиджарет А.С. | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент |
US20150202148A1 (en) | 2012-07-05 | 2015-07-23 | Arven llac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
DE102012211907A1 (de) * | 2012-07-09 | 2014-01-09 | Robert Bosch Gmbh | Drehschlagschrauber mit einem Schlagwerk |
GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
CN105392471A (zh) | 2013-05-22 | 2016-03-09 | 珍珠治疗公司 | 用于呼吸递送三种或更多种活性剂的组合物、方法和系统 |
WO2015094927A1 (en) | 2013-12-17 | 2015-06-25 | Merck Sharp & Dohme Corp. | Media milling process for the manufacture of active pharmaceutical ingredients in propellants |
-
2015
- 2015-09-09 UA UAA201703025A patent/UA115958C2/uk unknown
- 2015-09-09 NZ NZ728435A patent/NZ728435A/en unknown
- 2015-09-09 CN CN201580048064.1A patent/CN106604720B/zh active Active
- 2015-09-09 SG SG11201700536XA patent/SG11201700536XA/en unknown
- 2015-09-09 HU HUE15762595A patent/HUE049339T2/hu unknown
- 2015-09-09 MA MA40617A patent/MA40617B1/fr unknown
- 2015-09-09 MA MA050680A patent/MA50680A/fr unknown
- 2015-09-09 MX MX2017003080A patent/MX2017003080A/es active IP Right Grant
- 2015-09-09 TN TN2017000077A patent/TN2017000077A1/en unknown
- 2015-09-09 US US15/509,769 patent/US10532041B2/en active Active
- 2015-09-09 RS RS20200579A patent/RS60299B1/sr unknown
- 2015-09-09 PT PT157625955T patent/PT3191081T/pt unknown
- 2015-09-09 AR ARP150102874A patent/AR101793A1/es not_active Application Discontinuation
- 2015-09-09 BR BR112017003888-9A patent/BR112017003888B1/pt active IP Right Grant
- 2015-09-09 TW TW104129823A patent/TWI602566B/zh active
- 2015-09-09 EP EP15762595.5A patent/EP3191081B1/en active Active
- 2015-09-09 EP EP20165232.8A patent/EP3689332A1/en active Pending
- 2015-09-09 AP AP2017009777A patent/AP2017009777A0/en unknown
- 2015-09-09 ES ES15762595T patent/ES2793905T3/es active Active
- 2015-09-09 CA CA2960694A patent/CA2960694C/en active Active
- 2015-09-09 PL PL15762595T patent/PL3191081T3/pl unknown
- 2015-09-09 DK DK15762595.5T patent/DK3191081T3/da active
- 2015-09-09 LT LTEP15762595.5T patent/LT3191081T/lt unknown
- 2015-09-09 EA EA201790544A patent/EA037332B1/ru unknown
- 2015-09-09 WO PCT/EP2015/070660 patent/WO2016038116A1/en active Application Filing
- 2015-09-09 AU AU2015314272A patent/AU2015314272B2/en active Active
- 2015-09-09 KR KR1020177009495A patent/KR101927960B1/ko active IP Right Grant
- 2015-09-09 SI SI201531220T patent/SI3191081T1/sl unknown
- 2015-09-09 JP JP2017532216A patent/JP6502501B2/ja active Active
- 2015-09-09 MY MYPI2017700336A patent/MY181647A/en unknown
-
2017
- 2017-01-26 ZA ZA2017/00658A patent/ZA201700658B/en unknown
- 2017-02-02 IL IL250427A patent/IL250427A0/en active IP Right Grant
- 2017-02-17 PH PH12017500303A patent/PH12017500303A1/en unknown
- 2017-03-07 SV SV2017005403A patent/SV2017005403A/es unknown
- 2017-03-08 DO DO2017000065A patent/DOP2017000065A/es unknown
- 2017-03-08 CL CL2017000560A patent/CL2017000560A1/es unknown
- 2017-03-29 CO CONC2017/0003056A patent/CO2017003056A2/es unknown
- 2017-04-06 EC ECIEPI201721465A patent/ECSP17021465A/es unknown
-
2019
- 2019-12-03 US US16/701,616 patent/US20200155506A1/en not_active Abandoned
-
2020
- 2020-06-17 CY CY20201100560T patent/CY1124569T1/el unknown
- 2020-06-25 HR HRP20201005TT patent/HRP20201005T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123853T1 (el) | Ρυθμιστες nrf2 | |
CY1124569T1 (el) | Φαρμακοτεχνικη μορφη που περιεχει γλυκοπυρρολικο, μεθοδος και συσκευη | |
DK3214081T3 (da) | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
BR112016020112A2 (pt) | anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica | |
EA202092987A2 (ru) | Липид, содержащий докозапентаеновую кислоту | |
WO2016007617A3 (en) | Pharmaceutical compounding kit | |
BR112017012210A2 (pt) | solução conservante de célula, uso da mesma e método de produção de solução conservante de célula | |
CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
EA201692043A1 (ru) | Лекарственная форма иммунодепрессанта | |
PH12016502002B1 (en) | Novel bacteriophage and composition comprising same | |
CL2018000517A1 (es) | Método de elaboración de papel lignocelulósico y productos de papel. | |
MA40313A (fr) | Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale | |
UA116697C2 (uk) | Композиція для запобігання зараженню видами роду mycoplasma | |
MX2016015465A (es) | Composicion farmaceutica oral de isotretinoina. | |
EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
KR102374939B9 (ko) | 경화성 조성물, 경화물 및 경화물의 제조 방법 | |
EP3321014A4 (en) | Method for producing platinum colloid, and platinum colloid produced using such method | |
EA201691793A1 (ru) | Способ получения состава на основе вилдаглиптина в атмосфере инертного газа | |
MY175821A (en) | Microorganism having ability to produce o-succinylhomoserine or succinic acid, and method for producing succinic acid or o-succinylhomoserine by using same | |
CY1120746T1 (el) | Παιδιατρικο μασωμενο δισκιο που περιεχει αντιικο παραγοντα και μεθοδος για την παρασκευη του | |
CY1120402T1 (el) | Νεο αλας ιμβαμπραδινης και μεθοδος παρασκευης αυτου | |
CY1120037T1 (el) | Μια διαδικασια για παραγωγη συμπλοκων σιδηρου (iii) ν-ακετυλο-ασπαρτυλιωμενης καζεϊνης και χρηση αυτων σε φαρμακευτικες συνθεσεις | |
EA201891719A1 (ru) | Светостойкий экстракт хмеля | |
FR3026009B1 (fr) | Nanocapsules lipidiques, compositions pharmaceutiques, procede de preparation, et utilisations correspondants |